Clinical Trials And Drug DevelopmentElevation continues to enroll patients into the dose expansion portion of the ongoing Phase 1 Study evaluating EO-3021 as a monotherapy to treat advanced unresectable cancers.
Market Potential And Competitive PositioningEO-3021 results from partner CSPC in China in unselected CLDN patients are on par or superior to the FiH data in CLDN-selected patients of two new competitors.
Safety And TolerabilityGiven the favorable reported safety profile, no grade 4 or 5 treatment-emergent adverse events (TEAEs) were reported, which indicates strong potential for EO-3021 as a combination therapy.